Literature DB >> 807313

Treatment of chromophobe adenmas with megavoltage tirradiation.

D A Pistenma, D R Goffinet, M A Bagshaw, J W Hanbery, J R Eltringham.   

Abstract

From 1956-1972, 62 previously untreated patients with chromophobe adenomas received high-dose (average equivalent dose: 5700rads in 6 weeks) megavoltage (4-4.8 MeV) irradiation at Stanford, 33 postoperatively and 29 as the only intended treatment. Initialtreatment failure rates were 18% and 41%, respectively; however, overall control was 85% and 90%, despite 2 uncontrolled "invasive" adenomas in each group. Nine of the 12 failures in the group treated by irradiation alone had cystic tumors, and 9 of the 12 "failed" in less than 3 months. Despite a considerably greater degree of abnormal vision initially in the postoperative irradiation group, improvement of vision with treatment in that group was 83% (19% returned to normal) compared to 46% (only 8% to normal) in the irradiation alone group. Based upon an evaluation of the extent of findings at diagnosis and our results, we recommend surgical decompression followed by 5000 rads in 5 weeks for patients with any one or more of the following findings: 1)more than minimal depression of peripheral visual fields; 2) corrected visual actuity of less than 20/30 in either eye; or 3)more than 1-cm suprasellar extension of tumor. We recommend irradiation alone, as specified, for smaller adenomas accompanied by less extensive or no visual abnormalities.

Entities:  

Mesh:

Year:  1975        PMID: 807313     DOI: 10.1002/1097-0142(197506)35:6<1574::aid-cncr2820350615>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Delayed radiation necrosis of the central nervous system in patients irradiated for pituitary tumours.

Authors:  P J Grattan-Smith; J G Morris; A O Langlands
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

2.  Results of surgery and irradiation or irradiation alone for pituitary adenomas.

Authors:  P W Grigsby; J R Simpson; S Stokes; J E Marks; B Fineberg
Journal:  J Neurooncol       Date:  1988-09       Impact factor: 4.130

3.  Postoperative radiation therapy for pituitary adenoma.

Authors:  K Isobe; M Ohta; S Yasuda'; T Uno; R Hara; N Machida; N Saeki; A Yamaura; N Shigematsu; H Ito
Journal:  J Neurooncol       Date:  2000-06       Impact factor: 4.130

4.  Immunohistochemistry as a predictor of clinical outcome in patients given postoperative radiation for subtotally resected pituitary adenomas.

Authors:  J J Kovalic; G Mazoujian; D W McKeel; B B Fineberg; P W Grigsby
Journal:  J Neurooncol       Date:  1993-06       Impact factor: 4.130

5.  Pituitary oncocytomas: clinical features, characteristics in cell culture, and treatment recommendations.

Authors:  D L Silbergeld; M R Mayberg; M S Berger; F Ali-Osman; W A Kelly; C M Shaw
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.